Cannabis Leader GW Pharma Could Get US Approval Early 2016

One of the biggest names in the medical cannabis sector seems poised to enter the United States market soon.

The British company GW Pharma, known for its marijuana-derived drug Epidiolex, reportedly could get approval for the drug from the US Food and Drug Administration (FDA) in early 2016.

Epidiolex contains the medical cannabis substance cannabidiol (CBD) and is primarily used to treat epilepsy. Currently, the drug has a fast-track status from the FDA. It is also in its final Phase 3 study for the treatment of pediatric epilepsy disorders, and results are expected in the first quarter of 2016, reported the Huffington Post.

Writing for the publication, medical cannabis advocate Alice O’Leary Randall said that Epidiolex is anticipated to “breeze through this final stage”. If it does, it could be on the US market in the first half of next year.

Because Epidiolex is a marijuana product, shipping it from the UK would be highly complicated, especially in the face of US federal regulations. GW Pharmaceuticals will likely need to invest in infrastructure in order to grow cannabis within the US, and then manufacture the drug in the states where it wants to sell it.

Posted in: Articles

Comments are closed.